| MiroBio–Advent Life Sciences: investment, 202206 financing round Series B totalling £80m incl existing + co-investor Advemt Life Sciences |
2022-06-29 |
| MiroBio–Monograph Capital: investment, 202206 financing round Series B totalling £80m incl new + co-investor Monograph Capital |
2022-06-29 |
| MiroBio–OrbiMed: investment, 202206 financing round Series B totalling £80m incl new + co-investor OrbiMed |
2022-06-29 |
| MiroBio–Samsara Biocapital: investment, 202206 financing round Series B totalling £80m incl existing + co-investor Samsara Biocapital |
2022-06-29 |
| MiroBio–SR One: investment, 202206 financing round Series B totalling £80m incl existing + co-investor SR One |
2022-06-29 |
| MiroBio–Univ Oxford: investment, 202206 financing round Series B totalling £80m incl existing + co-investor Oxford Science Enterprises |
2022-06-29 |
| Dunad Therapeutics–Ten Bridge Communications: public relations, 202206 service existent Ten Bridge is media contact |
2022-06-28 |
| Menarini–NewAmsterdam Pharma: obicetrapib, 202206– license excl €115m upfront + €27.5m funding + €863m milestones for cardiovascular in Europe |
2022-06-28 |
| Epizyme–Ipsen: investment, 202206– cash tender offer $247m + 1CVR/share ANNOUNCED |
2022-06-27 |
| Micropep Technologies–SEVERAL: investment, 202206 financing round Series A1 €8.75m led by new investor Fall Line Capital |
2022-06-27 |
| Epoch Biodesign–BoxGroup: investment, 202206c seed financing round totalling $11m incl co-investor BoxGroup |
2022-06-22 |
| Epoch Biodesign–Lowercarbon Capital: investment, 202206c seed financing round totalling $11m incl lead investor Lowercarbon Capital |
2022-06-22 |
| Epoch Biodesign–SEVERAL: investment, 202206c seed financing round $11m led by Lowercarbon Capital |
2022-06-22 |
| SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures |
2022-06-22 |
| Abound Bio–Galapagos: investment, 202206 acquisition $14m in cash of AboundBio by Galapagos |
2022-06-21 |
| CellPoint–Galapagos: investment, 202206 acquisition in cash €125m upfront + €100m milestones of CellPoint by Galapagos |
2022-06-21 |
| JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica |
2022-06-14 |
| Spirea–R42 Group: investment, 202206 financing round totalling £2.4m incl co-investor R42 Group |
2022-06-14 |
| Spirea–SEVERAL: investment, 202206 financing round £2.4m led by Jonathan Milner + Cambridge Enterprise |
2022-06-14 |
| ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners |
2022-06-13 |
| Charm Therapeutics–Axial: investment, 202206 financing round Series A totalling $50m incl co-investor Axial |
2022-06-09 |
| Charm Therapeutics–Braavos Investment Advisers: investment, 202206 financing round Series A totalling $50m incl co-investor Braavos |
2022-06-09 |
| Charm Therapeutics–F-Prime: investment, 202206 financing round Series A totalling $50m incl co-lead investor F-Prime Capital |
2022-06-09 |
| Charm Therapeutics–General Catalyst: investment, 202206 financing round Series A totalling $50m incl co-investor General Catalyst |
2022-06-09 |
| Charm Therapeutics–Khosla Ventures: investment, 202206 financing round Series A totalling $50m incl co-investor Khosla Ventures |
2022-06-09 |
| Charm Therapeutics–OrbiMed: investment, 202206 financing round Series A totalling $50m incl co-lead investor OrbiMed |
2022-06-09 |
| Charm Therapeutics–SEVERAL: investment, 202206 financing round Series A $50m co-led by F-Prime Capital + OrbiMed |
2022-06-09 |
| Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap |
2022-06-09 |
| Peptone–Bessemer Venture: investment, 202206 financing round Series A totalling $40m incl co-lead investor Bessemer Venture Partners |
2022-06-09 |
| Peptone–F-Prime: investment, 202206 financing round Series A totalling $40m incl co-lead investor F-Prime Capital |
2022-06-09 |
| Peptone–Hoxton Ventures: investment, 202206 financing round Series A totalling $40m incl existing + co-investor Hoxton Ventures |
2022-06-09 |
| Peptone–Novartis: investment, 202206 financing round Series A totalling $40m incl existing + co-investor dRX Capital |
2022-06-09 |
| Peptone–Nvidia: AI-based drug discovery, 202206 collab incl use of Nvidia DGX A100 supercomputer to run Peptone’s algorithmic engine |
2022-06-09 |
| Peptone–SEVERAL: investment, 202206 financing round Series A $40m led by F-Prime + Bessemer Venture Partners |
2022-06-09 |
| Peptone–Walden Catalyst: investment, 202206 financing round Series A totalling $40m incl co-investor Walden Catalyst Vemtures |
2022-06-09 |
| Relation Therapeutics–SEVERAL: investment, 202206 seed financing round $25m co-led by DCVC + Magentic Ventures |
2022-06-09 |
| Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences |
2022-06-08 |
| Frame Cancer Therapeutics–CureVac: investment, 202206 acquisition in shares €32m with €16m upfront + €16m milestones |
2022-06-08 |
| ImmunOs Therapeutics–BioMedPartners: investment, 202206 financing round Series B totalling $74m incl existing + co-investor BioMedPartners |
2022-06-07 |
| ImmunOs Therapeutics–Fiscus Financial: investment, 202206 financing round Series B totalling $74m incl new + co-investor Fiscus Financial |
2022-06-07 |
| ImmunOs Therapeutics–Gimv: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Gimv |
2022-06-07 |
| ImmunOs Therapeutics–GL Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor GL Capital |
2022-06-07 |
| ImmunOs Therapeutics–Lightspeed Venture Partners: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Lightspeed VP |
2022-06-07 |
| ImmunOs Therapeutics–Mission BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Mission BioCapital |
2022-06-07 |
| ImmunOs Therapeutics–Peak6 Strategic Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Peak6 |
2022-06-07 |
| ImmunOs Therapeutics–Pfizer: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Pfizer Ventures |
2022-06-07 |
| ImmunOs Therapeutics–Samsara BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Samsara BioCapital |
2022-06-07 |
| ImmunOs Therapeutics–Schroders: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Schroder Adveq |
2022-06-07 |
| ImmunOs Therapeutics–SEVERAL: investment, 202206 financing round Series B $74m led by Samsara BioCapital + Lightspeed VP + Gimv |
2022-06-07 |
| Turning Point Therapeutics–BMS: investment, 202206– acquisition cash tender offer $4.1b at $76/share |
2022-06-03 |
| Vizgen–ARCH Venture: investment, 202206 financing round Series C totalling $85.2m incl existing + co-lead investor ARCH Venture Partners |
2022-06-03 |
| Vizgen–Blue Water Life Science Advisors: investment, 202206 financing round Series C totalling $85.2m incl co-lead investor Blue Water LSA |
2022-06-03 |
| Vizgen–Northpond Ventures: investment, 202206 financing round Series C totalling $85.2m incl existing + co-investor Northpond Ventures |
2022-06-03 |
| Vizgen–Novalis LifeSciences: investment, 202206 financing round Series C totalling $85.2m incl co-investor Novalis LifeSciences |
2022-06-03 |
| Vizgen–PERSON: investment, 202206 financing round Series C totalling $85.2m incl co-investor David Walt |
2022-06-03 |
| Vizgen–SEVERAL: investment, 202206 financing round Series C $85.2m co-led by Blue Water Life Science + ARCH Venture Partners |
2022-06-03 |
| Vizgen–Sofina: investment, 202206 financing round Series C totalling $85.2m incl co-investor Sofina |
2022-06-03 |
| Vizgen–Tao Capital: investment, 202206 financing round Series C totalling $85.2m incl co-investor Tao Capital Partners |
2022-06-03 |
| BMS–Immatics: cancer immunotherapy, 202201– collab strategic alliance expansion $60m upfront + $700 milestones per programme using ACTallo platform |
2022-06-02 |
| Transition Bio–SEVERAL: investment, 202206 financing round Series A $50m led by Northpond Ventures |
2022-06-02 |
| Watchmaker Genomics–Decheng Capital: investment, 202206 financing round Series A totalling $40m incl lead investor Decheng Capital |
2022-06-02 |
| Watchmaker Genomics–Eclipse Ventures: investment, 202206 financing round Series A totalling $40m incl co-investor Eclipse Ventures |
2022-06-02 |
| Watchmaker Genomics–SEVERAL: investment, 202206 financing round Series A $40m led by Decheng Capital |
2022-06-02 |
| Affinivax–GSK: investment, 202205– acquisition 100% for $2.1b upfront + $1.2b milestones by GSK ANNOUNCED |
2022-05-31 |
| Repertoire Genesis–Eurofins: investment, 202205 acquisition of majority stake by Eurofins Scientific |
2022-05-31 |
| Ultima Genomics–aMoon: investment, 202205 emerges from stealth with $600m incl investor aMoon |
2022-05-31 |
| Ultima Genomics–Andreessen Horowitz: investment, 202205 emerges from stealth with $600m incl investor a16z |
2022-05-31 |
| Ultima Genomics–D1 Capital: investment, 202205 emerges from stealth with $600m incl investor D1 Capital |
2022-05-31 |
| Ultima Genomics–Founders Fund: investment, 202205 emerges from stealth with $600m incl investor Founders Fund |
2022-05-31 |
| Ultima Genomics–General Atlantic: investment, 202205 emerges from stealth with $600m incl investor General Atlantic |
2022-05-31 |
| Ultima Genomics–Khosla Ventures: investment, 202205 emerges from stealth with $600m incl investor Khosla Ventures |
2022-05-31 |
| Ultima Genomics–Lightspeed Venture Partners: investment, 202205 emerges from stealth with $600m incl investor Lightspeed |
2022-05-31 |
| Ultima Genomics–PERSON: investment, 202205 emerges from stealth with $600m incl investor Marius Nacht |
2022-05-31 |
| Ultima Genomics–Playground Global: investment, 202205 emerges from stealth with $600m incl investor Playground Global |
2022-05-31 |
| Ultima Genomics–SEVERAL: investment, 202205 emerges from stealth with $600m raised from leading life science investors |
2022-05-31 |
| Advent Life Sciences–Scius Communications: public relations, 202205 supply service existent by Scius Communications |
2022-05-26 |
| ProFound Therapeutics–Flagship Pioneering: investment, 202205 Flagship unveils ProFound Tx with $75m initally committed |
2022-05-26 |
| uMotif–Athyrium Capital: investment, 202205 investment $25.5m from fund managed by Athyrium Capital Management LP |
2022-05-25 |
| Pancryos–Partners HealthCare: drug delivery technology, 202205– license ww excl from BWH for ceMED for delivery of PanINSULA |
2022-05-24 |
| Cygnal Therapeutics–Inzen Therapeutics: investment, 202205 merger of Flaghsip companies Inzen Tx + Cygnal Tx into Sonata Therapeutics |
2022-05-18 |
| SwanBio Therapeutics–Mass General Brigham Ventures: investment, 202205 financing round Series B totalling $56m incl existing + co-lead investor MGBV |
2022-05-18 |
| SwanBio Therapeutics–SEVERAL: investment, 202205 financing round Series B $56m led by founding investors Syncona Ltd + Mass General Brigham Ventures |
2022-05-18 |
| SwanBio Therapeutics–Syncona: investment, 202205 financing round Series B totalling $56m incl existing + co-lead investor Syncona Ltd |
2022-05-18 |
| Apollo Global Management–Sofinnova: life science financing, 202205– strategic partnership incl investm in Sofinnova Partners + up to $1b capital |
2022-05-16 |
| Kriya Therapeutics–Patient Square Capital: investment, 202205 financing round Series C totalling $270m incl lead investor Patient Square Capital |
2022-05-16 |
| Kriya Therapeutics–SEVERAL: investment, 202205 financing round Series C $270m led by Patient Square Capital |
2022-05-16 |
| Sofinnova–Apollo Global Management: investment, 202205– acquisition of minority equity interest in Sofinnova Partners as part of strategic partnership |
2022-05-16 |
| Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo |
2022-05-16 |
| Artax Biopharma–Advent Life Sciences: investment, 202205 financing round totalling $26m incl existing investor Advent Life Sciences |
2022-05-11 |
| Artax Biopharma–Columbus Venture Partners: investment, 202205 financing round totalling $26m incl existing investor Columbus Venture Partners |
2022-05-11 |
| Artax Biopharma–Lilly: investment, 202205 financing round totalling $26m incl new investor Eli Lilly |
2022-05-11 |
| Artax Biopharma–PERSON: investment, 202205 financing round totalling $26m incl existing investor Belinda Termeer |
2022-05-11 |
| Artax Biopharma–SEVERAL: investment, 202205 financing round $26m with new investors Eli Lilly + Sound Bioventures et al |
2022-05-11 |
| Artax Biopharma–Sound Bioventures: investment, 202205 financing round totalling $26m incl new investor Sound Bioventures |
2022-05-11 |
| Domain Therapeutics–BPCE: investment, 202205 financing round Series A totalling €39m incl existing + co-investor Seventure Partners |
2022-05-10 |
| Domain Therapeutics–Canada (govt): investment, 202205 financing round Series A totalling €39m incl co-investor adMare BioInnovations |
2022-05-10 |
| Domain Therapeutics–CTI Life Sciences: investment, 202205 financing round Series A totalling €39m incl co-lead investor CTI Life Sciences |
2022-05-10 |
| Domain Therapeutics–Helsinn: investment, 202205 financing round Series A totalling €39m incl co-lead investor 3B Future Health Fund |
2022-05-10 |
| Domain Therapeutics–Omnes Capital: investment, 202205 financing round Series A totalling €39m incl co-investor Omnes |
2022-05-10 |
| Domain Therapeutics–Panacea Venture: investment, 202205 financing round Series A totalling €39m incl co-lead investor Panacea Venture |
2022-05-10 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
